Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18432028 | Engineered Therapeutic Probiotic System and Method | February 2024 | January 2026 | Allow | 23 | 2 | 0 | Yes | No |
| 17912461 | HETEROCLITIC CANCER VACCINES | September 2022 | March 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17796152 | ANTI-B7-H4 CONSTRUCTS AND USES THEREOF | July 2022 | February 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17784585 | THERAPEUTIC COMPOSITIONS COMPRISING AN AMYLOID BETA ANTIBODY OR VACCINE FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | June 2022 | February 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17778617 | NOVEL IMMUNOTHERAPIES TARGETING PD-1 WITH ANTI-PD-1/IL-15 IMMUNOCYTOKINES | May 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17778522 | METHODS OF TREATING GLIOBLASTOMA | May 2022 | February 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17716248 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17763906 | VCX/Y PEPTIDES AND USE THEREOF | March 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17620271 | COMBINATION THERAPY | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17618716 | T-Cell Receptor for Treating Fibrolamellar Hepatocellular Carcinoma | December 2021 | October 2025 | Allow | 46 | 1 | 1 | No | No |
| 17612432 | IL-2/IL-15R BETA GAMMA AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES | November 2021 | February 2026 | Allow | 51 | 2 | 1 | No | No |
| 17612052 | BISPECIFIC T-CELL ENGAGER WITH CLEAVABLE CYTOKINES FOR TARGETED IMMUNOTHERAPY | November 2021 | October 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17612212 | CHIMERIC ANTIGEN RECEPTOR TARGETING CLL1 AND USE THEREOF | November 2021 | October 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17366343 | TARGETED MUTANT INTERFERON-GAMMA AND USES THEREOF | July 2021 | September 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17418884 | METHOD FOR DETECTING THE PRESENCE AND QUANTITY OF THE LRP8 RECEPTOR AND OF ITS PROTEOLYTIC FRAGMENTS, DETECTION KIT AND RELATED ANTIBODIES | June 2021 | September 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17292907 | NOVEL C-MET AND TMX2 ANTIBODIES | May 2021 | December 2025 | Allow | 55 | 3 | 1 | No | No |
| 16894468 | METHODS AND REAGENTS FOR REDUCING THE INTERFERENCE OF DRUGS THAT BIND CD47 IN SEROLOGICAL ASSAYS | June 2020 | October 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 14543277 | FLT4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY | November 2014 | October 2015 | Allow | 11 | 0 | 0 | Yes | No |
| 13770677 | LOW FREQUENCY GLATIRAMER ACETATE THERAPY | February 2013 | October 2014 | Allow | 20 | 2 | 0 | Yes | No |
| 13308299 | LOW FREQUENCY GLATIRAMER ACETATE THERAPY | November 2011 | June 2012 | Allow | 6 | 1 | 0 | Yes | No |
| 10505313 | ANTI-AMYLOID BETA ANTIBODIES | March 2005 | August 2009 | Allow | 60 | 2 | 1 | Yes | No |
| 10331289 | HUMAN METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE MGLUR7B | December 2002 | April 2006 | Allow | 39 | 0 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner STUCKER, JEFFREY J works in Art Unit 1675 and has examined 14 patent applications in our dataset. With an allowance rate of 78.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner STUCKER, JEFFREY J's allowance rate of 78.6% places them in the 47% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by STUCKER, JEFFREY J receive 1.29 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by STUCKER, JEFFREY J is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +20.8% benefit to allowance rate for applications examined by STUCKER, JEFFREY J. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 40.0% of applications are subsequently allowed. This success rate is in the 90% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 7.1% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.